^
BIOMARKER:

CYP17A1 expression

i
Other names: Cytochrome P450 Family 17 Subfamily A Member 1, Steroid 17-Alpha-Monooxygenase, Cytochrome P450 Subfamily XVII (Steroid 17-Alpha-Hydroxylase), Adrenal Hyperplasia, Cytochrome P450 Family 17 Subfamily A Polypeptide 1, Steroid 17-Alpha-Hydroxylase/17 20 Lyase, 17-Alpha-Hydroxyprogesterone Aldolase, Cytochrome P450 17A1, Cytochrome P450-C17, Cytochrome P450c17, CYPXVII, CYP17, S17AH, Cytochrome P450 XVIIA1, P450C17, CPT7, CYP17A1
Entrez ID:
Related biomarkers:
2ms
Our data suggest that developmental exposure to CD leads to epigenetic changes in prostate tissue. The PIN containing samples showed evidence of implication in hormonal pathway and self-renewal gene expression that have the capacity to promote neoplasia in CD-exposed mice.
Journal • Epigenetic controller
|
RB1 (RB Transcriptional Corepressor 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • HOXA9 (Homeobox A9) • CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • NANOG (Nanog Homeobox) • SOX2
|
CYP17A1 expression
3ms
The A/A allele was also found associated with reduced expression of FTO, suggesting an epi-transcriptomic mechanism may underlie the dysregulation of genes involved in hormonal biosynthesis leading to an increased risk of breast cancer. These findings provide evidence that genetic variants govern high levels of expression variance in breast tissue, thus building a more comprehensive insight into the underlying biology of breast cancer risk loci.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
|
CYP17A1 expression • FTO expression
5ms
For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
Preclinical
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
5ms
CYP17A1-induced DNA demethylation can inhibit proliferation, invasion, and metastasis of glioma cells.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
|
temozolomide
6ms
Our data suggest that HMGCR overexpression in adult ACC might lead to intracellular isoprenoid accumulation and cell proliferation. Therefore, the mevalonate pathway is a potential target for ACC treatment.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
7ms
SMIM28 was revealed to possibly have a role in tumor proliferation and aggressiveness. Our results indicate that these DEGs can serve as prognostic indicators of survival in high-risk neuroblastoma patients and will assist clinicians in making better therapeutic and patient management decisions.
Journal • Gene Expression Profile
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
10ms
Our study demonstrated that the TGF-β/Smad3 signaling pathway was involved in the inhibition of ovarian tissue fibrosis, which contributed to the restoration of ovarian function in POI rats following hUMSC transplantation.
Preclinical • Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
|
cisplatin
10ms
DNA methylation plays a regulatory role for CYP11B2 expression and may contribute to aldosterone hypersecretion in APA. Lower CYP11B2 methylation levels in APA than in APCCs may suggest an APCC-to-APA switch via progressive CYP11B2 demethylation. Conversely, DNA methylation seems not to be relevant in regulating the expression of genes encoding steroidogenic enzymes other than CYP11B2.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2)
|
CYP17A1 expression
11ms
CYP11B1 was the steroidogenic enzyme with the most discriminative power to distinguish ACC from ACAc, with a sensitivity of 100%, specificity of 92%, and an expression higher than 4.44%, indicating the presence of a cortisol secreting adenoma. ACC depicts an incomplete pattern of steroidogenic protein expression, with decreased CYP11B1 and CYP17A1, which could explain the predominant secretion of steroid precursors.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
11ms
In both variants, WT1(-KTS) has more obvious effects. In conclusion, WT1 can decrease progesterone secretion, likely due in part to the inhibition of CYP11A1 and 3β-HSD.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
11ms
Clostebol and oxymetholone might cause metabolic disturbances by suppressing corticosteroid production, resulting in adrenal hyperplasia. The non-steroidal SARMs exhibit an improved safety profile and represent a preferred therapeutic option.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2)
|
CYP17A1 expression
11ms
Several CYPs (CYP3A43, CYP2B6, CYP27A1, CYP24A1) can be considered as prognostic and diagnostic markers of prostate cancer. To propose personalized treatment, individual differences in CYP expression should be taken into account.
Clinical • Review • Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
12ms
In summary, the consensus data generated in this study highlight the unique and highly conserved nature of the ASPS transcriptome. Although the ability of the ASPL-TFE3 fusion to perturb mRNA expression must be acknowledged, the prevailing ASPS transcriptome resembles that of a mesenchymal stromal progenitor.
Retrospective data • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD36 (thrombospondin receptor) • CD9 • CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • ICAM1 (Intercellular adhesion molecule 1) • MCAM
|
HIF1A expression • CYP17A1 expression
12ms
Our analysis reveals a novel finding of increased expression of AKR1C3, HSD17B1, SRD5A2, SULT2A1, and EST in ovarian SCT-NOS, which is clinically associated with androgen excess and virilization. Further studies are needed to validate these enzymes as new markers in the evaluation of hyperandrogenic ovarian conditions.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • SULT1E1 (Sulfotransferase Family 1E Member 1)
|
CYP17A1 expression
1year
IHC-guided mKCNJ5 APA capture and steroid extraction identified a distinct intratumoral hybrid steroid signature that associated with co-expression of CYP11B2 and CYP17A1.These findings also demonstrate that OCT-embedded tissue can be used to accurately define intra-tissue steroid profiles, which will have application for steroid-producing and steroid-responsive tumors.
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
1year
Adrenals with clear zonal expression of CYP11B2 (ZG), HSD3B2 (ZG/ZF), and CYB5A (ZR) were included for study. Based on marker inclusion criteria, 3 ZG, 3 ZF, 3 ZR, and 3 medulla samples were studied. Using these samples, confirmatory markers of ZG (VSNL1), ZF (CYP17A1), ZR (SLC27A2), and medulla (TH) were analyzed by qPCR.
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
1year
Furthermore, H10 inhibited the adione-stimulated growth of xenografts established from LNCaP cells in nude mice in vivo. We conclude that H10 could serve as an effective inhibitor of 17β-HSD3, which in turn would inhibit the biosynthesis of androgens and progression of prostate cancer.
Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
CYP17A1 expression
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our